Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23FN4OS |
| Molecular Weight | 386.486 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC(=O)[C@@H](N)CCCCN)C=CC(=C1)C2=NC3=C(S2)C=CC(F)=C3
InChI
InChIKey=LFDOEFHQLNGBQQ-HNNXBMFYSA-N
InChI=1S/C20H23FN4OS/c1-12-10-13(20-25-17-11-14(21)6-8-18(17)27-20)5-7-16(12)24-19(26)15(23)4-2-3-9-22/h5-8,10-11,15H,2-4,9,22-23H2,1H3,(H,24,26)/t15-/m0/s1
| Molecular Formula | C20H23FN4OS |
| Molecular Weight | 386.486 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15377855 | https://www.ncbi.nlm.nih.gov/pubmed/15634650Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800021353
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15377855 | https://www.ncbi.nlm.nih.gov/pubmed/15634650
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800021353
5F-DF-203-L-LYSINAMIDE (Phortress) is an experimental antitumor agent with potent and selective activity against
human-derived carcinomas of breast, ovarian and renal origin. The mechanism of action of Phortress is distinct from all classes of chemotherapeutic
agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic
species, which generate DNA adducts in sensitive tumors only. Phortress is in phase I clinical trials for the treatment of solid tumours. The compound was co-developed by Pharminox, University of Nottingham and Cancer Research UK.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.31 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.27 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.239 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.415 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
50 patients were treated with 145 cycles of 5F-DF-203-L-LYSINAMIDE (Phortress) over a dose range of 3-50mg/m2. The first 6 patients were treated on d1,8 Q4weeks, 2 patients having DLTs. The protocol was amended to d1 q3weekly dosing, and escalated from 3 to 50 mg/m2 over 10 cohorts.
Route of Administration:
Intravenous
5F-DF-203-L-LYSINAMIDE caused a concentration-dependent cytokine response in precision-cut lung slice (PCLS) model. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE modestly elevated TNF-α within 24h, with average levels of TNF-α in PCLS
reaching 25 pg/mg, just above assay LLOD. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE for 72h increased tissue levels of IL-β, IL-5, and CINC. Exposure
to 50 and 100uM caused significant increases in PCLS content for all six cytokines analyzed.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:46:19 GMT 2023
by
admin
on
Sat Dec 16 13:46:19 GMT 2023
|
| Record UNII |
RF59KJ79DG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RF59KJ79DG
Created by
admin on Sat Dec 16 13:46:19 GMT 2023 , Edited by admin on Sat Dec 16 13:46:19 GMT 2023
|
PRIMARY | |||
|
741241-36-1
Created by
admin on Sat Dec 16 13:46:19 GMT 2023 , Edited by admin on Sat Dec 16 13:46:19 GMT 2023
|
PRIMARY | |||
|
399465
Created by
admin on Sat Dec 16 13:46:19 GMT 2023 , Edited by admin on Sat Dec 16 13:46:19 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
